Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thromboembolism 1Sarcoma 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 4Specimen Handling 3Magnetic Resonance Spectroscopy 3tislelizumab 2aflibercept 2Surveys and Questionnaires 2Radiotherapy 2Gene Expression Profiling 2Fentanyl 2Docetaxel 2Diet Therapy 2Blood Specimen Collection 2Biopsy 2trastuzumab deruxtecan 1toripalimab 1spartalizumab 1sargramostim 1rucaparib 1pegfilgrastim 1pazopanib 1olaparib 1milademetan 1entinostat 1durvalumab 1ciforadenant 1ceralasertib 1cemiplimab 1avelumab 1X-Rays 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Fondaparinux × Sarcoma × Clear all
NCT00381888 2017-12-28

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
44 enrolled 7 charts
GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Thromboembolism, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡